Study on the feasibility of fluorescence bronchoscopy with bevacizumab-800CW - DEFLECT I

Other illness

• History of infusion reactions to bevacizumab or other monoclonal antibodies according to the patient’s medical history
• Medical or psychiatric conditions that compromise the patient’s ability to give informed consent.

Other

• Pregnancy or breast feeding. A negative pregnancy test must be available for women of childbearing potential (i.e. premenopausal women with intact reproductive organs and women less than two years after menopause) on the day of tracer administration.

• Signed informed consent prior to participation in the study.
• Age ≥ 18 years.
• Patient has at least one intrabronchial, near-to-airway located or peripheral pulmonary nodule – with or without pathological lymph nodes – which is considered malignant (independent of its primary origin).
• Patient is considered fit to undergo a diagnostic and/or therapeutic bronchoscopy (with or without addition of virtual navigation and/or endobronchial ultrasound; including propofol sedation or general anesthesia if either is indicated) to obtain tumor material according to standard care protocols.